Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

1.

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Rodés J.

J Hepatol. 2004 Jan;40(1):140-6.

PMID:
14672625
[PubMed - indexed for MEDLINE]
2.

Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.

Fabrizi F, Dixit V, Messa P, Martin P.

Int J Artif Organs. 2009 Mar;32(3):133-40. Review.

PMID:
19440988
[PubMed - indexed for MEDLINE]
3.

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.

J Gastroenterol Hepatol. 2002 Aug;17(8):882-8.

PMID:
12164964
[PubMed - indexed for MEDLINE]
4.

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.

Gülberg V, Bilzer M, Gerbes AL.

Hepatology. 1999 Oct;30(4):870-5.

PMID:
10498636
[PubMed - indexed for MEDLINE]
5.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
[PubMed - indexed for MEDLINE]
6.

Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.

Testro AG, Wongseelashote S, Angus PW, Gow PJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1535-40. Epub 2008 Sep 3.

PMID:
17784863
[PubMed - indexed for MEDLINE]
7.

Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.

Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.

Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.

PMID:
19158001
[PubMed - indexed for MEDLINE]
8.

Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.

Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP.

Dig Dis Sci. 1996 Jun;41(6):1054-6.

PMID:
8654133
[PubMed - indexed for MEDLINE]
9.

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.

J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.

PMID:
12542598
[PubMed - indexed for MEDLINE]
10.

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.

J Hepatol. 2007 Oct;47(4):499-505. Epub 2007 May 24.

PMID:
17560680
[PubMed - indexed for MEDLINE]
11.

Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.

Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O.

Acta Gastroenterol Belg. 2001 Jan-Mar;64(1):15-9.

PMID:
11322061
[PubMed - indexed for MEDLINE]
12.

Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant.

Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein RM, Klintmalm GB.

Transplantation. 1997 Dec 27;64(12):1760-5.

PMID:
9422417
[PubMed - indexed for MEDLINE]
13.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
[PubMed - indexed for MEDLINE]
14.

Impact of pretransplant renal function on survival after liver transplantation.

Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS.

Transplantation. 1995 Feb 15;59(3):361-5.

PMID:
7871566
[PubMed - indexed for MEDLINE]
15.

Review article: pharmacological treatment of hepatorenal syndrome.

Ginès P, Torre A, Terra C, Guevara M.

Aliment Pharmacol Ther. 2004 Sep;20 Suppl 3:57-62; discussion 63-4. Review.

PMID:
15335404
[PubMed - indexed for MEDLINE]
16.

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators.

Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.

PMID:
18471512
[PubMed - indexed for MEDLINE]
17.

Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.

Dig Dis Sci. 2008 Mar;53(3):830-5. Epub 2007 Oct 16.

PMID:
17939047
[PubMed - indexed for MEDLINE]
18.

Terlipressin and albumin combination treatment in hepatorenal syndrome.

Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.

Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccciii-cccv.

PMID:
15244209
[PubMed - indexed for MEDLINE]
19.

Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.

Skagen C, Einstein M, Lucey MR, Said A.

J Clin Gastroenterol. 2009 Aug;43(7):680-5. doi: 10.1097/MCG.0b013e318188947c.

PMID:
19238094
[PubMed - indexed for MEDLINE]
20.

Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.

von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.

Z Gastroenterol. 2009 Jan;47(1):21-6. doi: 10.1055/s-0028-1109084. Epub 2009 Jan 20.

PMID:
19156588
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk